A narrower follow-up, since the general answer is now clear:
What a vetting checklist should actually contain, as opposed to a list of things that are easy to fake?
Dr.DermMIA said:The useful checklist is about verifiability rather than presentation.
Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:
| Feature | Platform A | Platform B | Platform C |
|---|---|---|---|
| Initial Consult | $78 | $88 | $0 |
| Monthly Follow-up | $38 | Included | $63 |
| Prescription Speed | Same day | 24-48 hours | Same day |
| Lab Monitoring | Required | Optional | Required |
I settled on the one that required labs — it shows they care about safety, not just prescribing volume.
Dr.DermMIA said:The useful checklist is about verifiability rather than presentation.
Financial impact of cost and coverage weight loss beyond medication cost:
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.DermMIA said:The useful checklist is about verifiability rather than presentation.
This is exactly what I could not find anywhere else. Printing the relevant bit and taking it with me.
Adding the clinical framing, because it changes how the question reads.
Dr.DermMIA said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.